These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

972 related articles for article (PubMed ID: 21969420)

  • 1. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia.
    Grant PM; Huh GA; Perivoliotis D; Stolar NM; Beck AT
    Arch Gen Psychiatry; 2012 Feb; 69(2):121-7. PubMed ID: 21969420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained and "sleeper" effects of group metacognitive training for schizophrenia: a randomized clinical trial.
    Moritz S; Veckenstedt R; Andreou C; Bohn F; Hottenrott B; Leighton L; Köther U; Woodward TS; Treszl A; Menon M; Schneider BC; Pfueller U; Roesch-Ely D
    JAMA Psychiatry; 2014 Oct; 71(10):1103-11. PubMed ID: 25103718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior.
    Hogarty GE; Flesher S; Ulrich R; Carter M; Greenwald D; Pogue-Geile M; Kechavan M; Cooley S; DiBarry AL; Garrett A; Parepally H; Zoretich R
    Arch Gen Psychiatry; 2004 Sep; 61(9):866-76. PubMed ID: 15351765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
    Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
    J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: an exploratory trial.
    Morrison AP; Hutton P; Wardle M; Spencer H; Barratt S; Brabban A; Callcott P; Christodoulides T; Dudley R; French P; Lumley V; Tai SJ; Turkington D
    Psychol Med; 2012 May; 42(5):1049-56. PubMed ID: 21914252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
    Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
    JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
    Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
    J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
    Umbricht D; Alberati D; Martin-Facklam M; Borroni E; Youssef EA; Ostland M; Wallace TL; Knoflach F; Dorflinger E; Wettstein JG; Bausch A; Garibaldi G; Santarelli L
    JAMA Psychiatry; 2014 Jun; 71(6):637-46. PubMed ID: 24696094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An RCT of adherence therapy for people with schizophrenia in Chiang Mai, Thailand.
    Maneesakorn S; Robson D; Gournay K; Gray R
    J Clin Nurs; 2007 Jul; 16(7):1302-12. PubMed ID: 17584349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial.
    Schoemaker JH; Jansen WT; Schipper J; Szegedi A
    J Clin Psychopharmacol; 2014 Apr; 34(2):190-8. PubMed ID: 24525661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effectiveness of individual cognitive behavioral therapy for depressed older people in primary care: a randomized controlled trial.
    Serfaty MA; Haworth D; Blanchard M; Buszewicz M; Murad S; King M
    Arch Gen Psychiatry; 2009 Dec; 66(12):1332-40. PubMed ID: 19996038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive-behavioural therapy for patients with schizophrenia: a multicentre randomized controlled trial in Beijing, China.
    Li ZJ; Guo ZH; Wang N; Xu ZY; Qu Y; Wang XQ; Sun J; Yan LQ; Ng RM; Turkington D; Kingdon D
    Psychol Med; 2015 Jul; 45(9):1893-905. PubMed ID: 25532460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
    Geffen Y; Keefe R; Rabinowitz J; Anand R; Davidson M
    J Clin Psychiatry; 2012 Sep; 73(9):e1168-74. PubMed ID: 23059159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic.
    Kitajima R; Miyamoto S; Tenjin T; Ojima K; Ogino S; Miyake N; Fujiwara K; Funamoto Y; Arai J; Tsukahara S; Ito Y; Tadokoro M; Anai K; Kaneda Y; Yamaguchi N
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):300-6. PubMed ID: 22122880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipsychotic treatment beyond antipsychotics: metacognitive intervention for schizophrenia patients improves delusional symptoms.
    Moritz S; Veckenstedt R; Randjbar S; Vitzthum F; Woodward TS
    Psychol Med; 2011 Sep; 41(9):1823-32. PubMed ID: 21275083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.